Filing Flows › Gossamer Bio (GOSS) › Q3 2025
Gossamer Bio (GOSS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Gossamer Bio (GOSS) reported revenue of $13.3M for the third quarter 2025 (Q3 2025), +40% from a year earlier and +16% from the quarter before. Operating margin was -369.4%, net loss $48.2M (362.7% of revenue).
Gossamer Bio, Q3 2025: revenue $13.3M (+40% year over year), operating margin -369.4%, net loss $48.2M, operating cash flow −$36.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.3M | +16% | +40% |
| Operating profit | −$49.1M | — | — |
| Net earnings | −$48.2M | — | — |
| Operating cash flow | −$36.2M | — | — |
What changed
Revenue was $13.3M in Q3 2025, up 40% year over year and up 16% from the previous quarter.
Operating costs exceeded revenue by $49.1M, an operating margin of -369.4%. Total costs grew 44% against revenue growth of 40%. The fastest-growing cost line was Research & development (+31%). The quarter ended with a net loss of $48.2M, wider than the previous quarter's $38.3M loss.
Operating cash flow was −$36.2M. Non-cash charges added back $6K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items added $9.4M.
Questions
What was Gossamer Bio's revenue in the third quarter 2025?
Gossamer Bio (GOSS) reported revenue of $13.3M for the third quarter 2025 (Q3 2025), +40% from a year earlier and +16% from the quarter before.
Was Gossamer Bio profitable in the third quarter 2025?
Operating loss was $49.1M (-369.4% of revenue) and net loss $48.2M.
Source: Gossamer Bio 10-Q on SEC EDGAR.